For the patients treated with apatinib monotherapy, the adverse events above grade 3 are mainly myelosuppression (9.3%), AST elevation (4.6%), ALT elevation (4.6%), hand-foot syndrome (7.0%), and elevated bilirubin (2.3%). The gene discussed is GPT; the disease is Hand-foot syndrome.